Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase.
Rafferty, Joseph A
Lashford, Linda S
Longhurst, S J
Margison, Geoffrey P
Dexter, T Michael
Fairbairn, Leslie J
AffiliationCRC Sections of Genome Damage and Repair, Paterson Institute for Cancer Research, Manchester, UK.
MetadataShow full item record
AbstractMurine bone marrow cells were transduced ex vivo with a retrovirus encoding an O6-benzylguanine (O6-beG) insensitive, double mutant form of the human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hATPA/GA). In animals reconstituted with the transduced bone marrow, about 50% of cells in the multipotent spleen colony-forming cells (CFU-S) and lineage restricted granulocyte-macrophage (GM-CFC) haemopoietic progenitor populations were found to be carrying the transgene and this correlated with the frequency of bone marrow cells and spleen colonies which stained positive for hATPA/GA by immunocyto-chemistry. Expression of hATPA/GA was associated with significant in vivo protection of both CFU-S (P = 0.001) and GM-CFC (P < 0.024) against the toxicity of the antitumour methylating agent, temozolomide, given in combination with O6-beG. Expression of hATPA/GA also led to a reduction in the frequency of combined O6-beG/temozolomide-induced micronuclei seen in polychromatic erythrocytes (P < 0.003). This study is the first to demonstrate in vivo protection of multipotent haemopoietic progenitors against the toxic and clastogenic effects of an O6-alkylating agent in the presence of O6-beG. It also represents the first report of reduced clastogenesis as a consequence of expression of an O6-beG-resistant ATase. In the accompanying article we report hATPA/GA-mediated resistance of human CD34+ haemopoietic progenitors to combined O6-beG/O6-alkylating agent toxicity. Together these two reports suggest that a gene therapy strategy whereby protection of normal haemopoietic tissue may be combined with O6-beG-mediated tumour sensitisation may be efficacious in achieving an increase in therapeutic index.
CitationChemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. 1998, 5 (6):842-7 Gene Ther.
- Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro.
- Authors: Hickson I, Fairbairn LJ, Chinnasamy N, Lashford LS, Thatcher N, Margison GP, Dexter TM, Rafferty JA
- Issue date: 1998 Jun
- Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase.
- Authors: Hickson I, Fairbairn LJ, Chinnasamy N, Dexter TM, Margison GP, Rafferty JA
- Issue date: 1996 Oct
- Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
- Authors: Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA
- Issue date: 2000 Feb
- Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy.
- Authors: Chinnasamy N, Rafferty J, Lashford L, Chinnasamy D, Margison G, Thatcher N, Dexter T, Fairbairn L
- Issue date: 1999 Nov
- Modulation of O6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells.
- Authors: Chinnasamy N, Fairbairn LJ, Laher J, Willington MA, Rafferty JA
- Issue date: 1998 Aug 7